Literature DB >> 21357542

Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus.

Mark W LaMere1, Ho-Tak Lam, Amy Moquin, Laura Haynes, Frances E Lund, Troy D Randall, Denise A Kaminski.   

Abstract

Influenza A virus causes recurring seasonal epidemics and occasional influenza pandemics. Because of changes in envelope glycoprotein Ags, neutralizing Abs induced by inactivated vaccines provide limited cross-protection against new viral serotypes. However, prior influenza infection induces heterosubtypic immunity that accelerates viral clearance of a second strain, even if the external proteins are distinct. In mice, cross-protection can also be elicited by systemic immunization with the highly conserved internal nucleoprotein (NP). Both T lymphocytes and Ab contribute to such cross-protection. In this paper, we demonstrate that anti-NP IgG specifically promoted influenza virus clearance in mice by using a mechanism involving both FcRs and CD8(+) cells. Furthermore, anti-NP IgG rescued poor heterosubtypic immunity in B cell-deficient mice, correlating with enhanced NP-specific CD8 T cell responses. Thus, Ab against this conserved Ag has potent antiviral activity both in naive and in influenza-immune subjects. Such antiviral activity was not seen when mice were vaccinated with another internal influenza protein, nonstructural 1. The high conservation of NP Ag and the known longevity of Ab responses suggest that anti-NP IgG may provide a critically needed component of a universal influenza vaccine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357542      PMCID: PMC3159153          DOI: 10.4049/jimmunol.1003057

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  77 in total

1.  Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.

Authors:  Suzanne E Ohmit; John C Victor; Judy R Rotthoff; Esther R Teich; Rachel K Truscon; Laura L Baum; Bhavya Rangarajan; Duane W Newton; Matthew L Boulton; Arnold S Monto
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

2.  Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus.

Authors:  Timothy J Powell; Tara Strutt; Joyce Reome; Joseph A Hollenbaugh; Alan D Roberts; David L Woodland; Susan L Swain; Richard W Dutton
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

3.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

4.  Fc receptor but not complement binding is important in antibody protection against HIV.

Authors:  Ann J Hessell; Lars Hangartner; Meredith Hunter; Carin E G Havenith; Frank J Beurskens; Joost M Bakker; Caroline M S Lanigan; Gary Landucci; Donald N Forthal; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nature       Date:  2007-09-06       Impact factor: 49.962

5.  Seasonal and pandemic influenza preparedness: a global threat.

Authors:  Richard J Whitley; Arnold S Monto
Journal:  J Infect Dis       Date:  2006-11-01       Impact factor: 5.226

6.  Effectiveness of influenza vaccine in the community-dwelling elderly.

Authors:  Kristin L Nichol; James D Nordin; David B Nelson; John P Mullooly; Eelko Hak
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

7.  Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire.

Authors:  Huan H Nguyen; Michael Zemlin; Ivaylo I Ivanov; Judit Andrasi; Cosima Zemlin; Huong L Vu; Robert Schelonka; Harry W Schroeder; Jiri Mestecky
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

8.  Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes.

Authors:  Biao Zheng; Yongxin Zhang; Hongxia He; Ekaterina Marinova; Kirsten Switzer; Daniel Wansley; Innocent Mbawuike; Shuhua Han
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

9.  Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production.

Authors:  Kei Yasuda; Christophe Richez; Joseph W Maciaszek; Neerja Agrawal; Shizuo Akira; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

10.  Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance.

Authors:  Stephanie O Harbers; Andrea Crocker; Geoffrey Catalano; Vivette D'Agati; Steffen Jung; Dharmesh D Desai; Raphael Clynes
Journal:  J Clin Invest       Date:  2007-04-19       Impact factor: 14.808

View more
  113 in total

1.  Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.

Authors:  Yuan Fang; David Banner; Alyson A Kelvin; Stephen S H Huang; Christopher J Paige; Steven A Corfe; Kevin P Kane; R Chris Bleackley; Thomas Rowe; Alberto J Leon; David J Kelvin
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  A Lipid/DNA Adjuvant-Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge.

Authors:  Timothy D Carroll; Sinthujan Jegaskanda; Shannon R Matzinger; Linda Fritts; Michael B McChesney; Stephen J Kent; Jeffery Fairman; Christopher J Miller
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

4.  Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.

Authors:  Paula A Lanthier; Gail E Huston; Amy Moquin; Sheri M Eaton; Frank M Szaba; Lawrence W Kummer; Micheal P Tighe; Jacob E Kohlmeier; Patrick J Blair; Michael Broderick; Stephen T Smiley; Laura Haynes
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

5.  Protection by universal influenza vaccine is mediated by memory CD4 T cells.

Authors:  Sophie A Valkenburg; Olive T W Li; Athena Li; Maireid Bull; Thomas A Waldmann; Liyanage P Perera; Malik Peiris; Leo L M Poon
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

6.  Narcolepsy and influenza vaccination-the inappropriate awakening of immunity.

Authors:  Anoma Nellore; Troy D Randall
Journal:  Ann Transl Med       Date:  2016-10

Review 7.  Inactivated influenza virus vaccines: the future of TIV and QIV.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Curr Opin Virol       Date:  2017-05-12       Impact factor: 7.090

8.  Smad4 promotes differentiation of effector and circulating memory CD8 T cells but is dispensable for tissue-resident memory CD8 T cells.

Authors:  Yinghong Hu; Young-Tae Lee; Susan M Kaech; Beth Garvy; Linda S Cauley
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

9.  Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Authors:  A F Altenburg; S E Magnusson; F Bosman; L Stertman; R D de Vries; G F Rimmelzwaan
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

10.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.